Developer docs
API playgroundTry for free, no card

Search company profiles

cardiomedex

Full company profile

uuid02m1vt3

Namestring
cardiomedex
Legal namestring
Cardiomedex SAS
Websiteurl
cardiomedex.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Cardiomedex is a French preclinical contract research organization (CRO) founded in 2011 by Dr. Thierry Sulpice and headquartered in Escalquens, near Toulouse, France. The company provides specialized research services for cardiovascular diseases and cardiometabolic complications, serving pharmaceutical and biotechnology clients globally. It operates as a subsidiary of Physiogenex, with which it shares facilities and scientific leadership, enabling an integrated operational backbone across cardiometabolic, metabolic, and renal disease research.

The company's core services are organized into four pillars: (1) in vivo disease models covering heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), myocardial infarction, cardiac hypertrophy, hypertension, and anthracycline-induced cardiotoxicity; (2) in vivo functional exploration using echocardiography, radiotelemetry, and Millar catheter probes for hemodynamic assessment; (3) ex vivo and in vitro assays including myograph and Langendorff isolated-heart preparations; and (4) consulting services for drug development and repositioning. Proprietary, validated disease models — notably a diet-induced NASH-HFpEF hamster model and the SDT fatty rat model for diabetic nephropathy — differentiate Cardiomedex's offering in the translational cardiovascular research market, where HFpEF and NASH-cardiac comorbidity have become high-priority indications for large-pharma pipelines.

Cardiomedex operates a project-based business model with custom-quoted, multi-year study contracts negotiated directly with client R&D teams, supplemented by consulting engagements. The company has no disclosed external funding and remains privately held. Customer acquisition is driven by direct sales, participation in major cardiology and metabolism conferences (AHA, ISHR, ISN, Keystone), peer-reviewed publications, and distribution partnerships such as the 2023 CLEA Japan agreement for the SDT fatty rat model. Cardiomedex also holds French Research Tax Credit (CIR) accreditation and operates in compliance with EU Directive 2010/63/EU for laboratory animal welfare, providing baseline eligibility for European preclinical outsourcing engagements.

Short descriptiontext

Cardiomedex is a France-based preclinical CRO founded in 2011, providing contract research services for cardiovascular and cardiometabolic drug development. It serves global pharmaceutical and biotechnology clients with proprietary animal models, functional exploration platforms, ex vivo assays, and drug-repositioning consulting.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEscalquens, France
HQ citystring
Escalquens
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical contract research, cardiovascular drug development, animal model studies, cardiometabolic research, preclinical CRO services
Industry3 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKABAA
General Cardiology (Consultative)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Other Scientific and Technical Consulting Services54169
Product category
Preclinical Contract Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Preclinical CRO Services
TypeProfessional Services
Description

Contract research organization providing fee-for-service preclinical studies for pharmaceutical and biotechnology companies evaluating cardiovascular drug candidates. Services include in vivo models, ex vivo/in vitro assays, and pharmacological characterization.

cardiomedex.com
2Consulting Services
TypeProfessional Services
Description

Strategy consulting services including research strategy development, study design and protocol development, literature research, medical writing, and strategic portfolio reviews for drug development and repositioning.

cardiomedex.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom CRO service packages tailored to client specifications
ModelOtherBilling cadenceMulti-year contract
Notes

Services are fully customized to comply with client specifications with pricing negotiated on a per-study basis.

cardiomedex.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cardiomedex is a preclinical contract research organization (CRO) that provides fee-for-service preclinical studies for pharmaceutical and biotechnology companies developing cardiovascular and cardiometabolic drugs. Its offering combines three service lines: in vivo animal models (HFpEF, HFrEF, myocardial infarction, cardiac hypertrophy, hypertension, NASH, diabetic nephropathy), in vivo functional exploration (echocardiography, telemetry, hemodynamic measurements), and ex vivo/in vitro assays (vascular reactivity, Langendorff perfused heart), supplemented by drug development consulting.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Successfully developed and validated NASH-HFpEF hamster model presented at AHA 2023 and ISHR 2023 conferences
+1 more record
Product overview1 text field

Cardiomedex is a preclinical Contract Research Organization (CRO) highly specialized in cardiovascular diseases and cardiometabolic complications. The company operates as a unified platform combining three interconnected service lines: In Vivo Models (pathophysiological animal models including HFpEF/HFrEF, myocardial infarction, cardiac hypertrophy, hypertension, and cardiometabolic models), In Vivo Exploration Platform (functional characterization via echocardiography, telemetry, hemodynamic measurements, and exercise testing), and Ex Vivo/In Vitro Assays (isolated organ studies and cellular assays). These core offerings are supplemented by personalized Consulting Services for drug development strategy, repositioning, and lifecycle management. Together, these services enable pharmaceutical and biotechnology companies to evaluate cardiac efficacy and safety of compounds using gold-standard and tailor-made experiments.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1CLEA Japan Inc.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-03-30
Description

Collaborative partnership with CLEA Japan Inc. for the SDT fatty rat model development. CLEA Japan provides the SDT fatty rat model expertise and business development support. Presented collaborative work at ISN-World Congress of Nephrology in Bangkok, Thailand in March-April 2023.

cardiomedex.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Physiogenex is a preclinical CRO specialized in metabolic disorders based in Toulouse, France with 15+ years of expertise. Cardiomedex and Physiogenex share the same CEO (Dr. Thierry Sulpice) and facilities. Together they provide an integrated approach to cardiometabolic diseases, enabling large-scale studies evaluating drug candidates on both cardiac and metabolic functions. Cardiomedex is a subsidiary company of Physiogenex.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large European-based CRO with extensive preclinical and clinical service lines, including cardiovascular safety pharmacology. Competes broadly for preclinical cardiovascular contracts across pharma sponsors.

TypeDirect peer
Description

Sister preclinical CRO sharing the same CEO (Dr. Thierry Sulpice), facilities in Escalquens, and a cardiometabolic focus. Directly comparable as a similarly sized French preclinical CRO serving pharma/biotech with metabolic disease models.

TypeBroad incumbent
Description

Global preclinical CRO with cardiovascular and metabolic disease models, including translational platforms for HFpEF, diabetes, and NASH. Competes with Cardiomedex on specialized cardiometabolic preclinical studies with greater geographic footprint.

TypeBroad incumbent
Description

Asia-based global CRO/CDMO with preclinical capabilities including cardiovascular and metabolic disease models. Competes on scale, integrated offerings, and cost for outsourced preclinical studies.

TypeBroad incumbent
Description

Global preclinical CRO with cardiovascular safety and efficacy capabilities across multiple species and therapeutic areas. Broad incumbent that competes with Cardiomedex on large cardiovascular preclinical programs but at vastly greater scale.

6Pelvipharm
TypeDirect peer
Description

French preclinical CRO specializing in vascular and women's health pharmacology, where Cardiomedex's Director of Business Development (Dr. Rana Assaly) was previously COO. Closely comparable in size, therapeutic niche, and French preclinical CRO model.

TypeBroad incumbent
Description

US-based preclinical CRO with cardiovascular safety pharmacology, toxicology, and disease model capabilities. Competitor for North American sponsor preclinical cardiovascular programs.

TypeEmerging player
Description

Preclinical CRO offering cardiovascular safety and efficacy profiling services. Comparable emerging player in specialized preclinical cardiovascular pharmacology for biotech sponsors.

TypeBroad incumbent
Description

Mid-sized CRO with strong cardiovascular therapeutic area presence, primarily clinical but with preclinical-adjacent relationships. Comparable as a cardiovascular-focused CRO serving pharma/biotech sponsors, though predominantly clinical-phase.

10Bienta (Enamine contract research)
TypeEmerging player
Description

Preclinical CRO with in vivo pharmacology capabilities across metabolic and cardiovascular indications. Comparable as a smaller, emerging preclinical CRO competing for European biotech preclinical contracts.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

cardiomedex

Preclinical Contract Research Servicescardiomedex.com

Cardiomedex is a France-based preclinical CRO founded in 2011, providing contract research services for cardiovascular and cardiometabolic drug development. It serves global pharmaceutical and biotechnology clients with proprietary animal models, functional exploration platforms, ex vivo assays, and drug-repositioning consulting.

What cardiomedex does

Cardiomedex is a French preclinical contract research organization (CRO) founded in 2011 by Dr. Thierry Sulpice and headquartered in Escalquens, near Toulouse, France. The company provides specialized research services for cardiovascular diseases and cardiometabolic complications, serving pharmaceutical and biotechnology clients globally. It operates as a subsidiary of Physiogenex, with which it shares facilities and scientific leadership, enabling an integrated operational backbone across cardiometabolic, metabolic, and renal disease research.

The company's core services are organized into four pillars: (1) in vivo disease models covering heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), myocardial infarction, cardiac hypertrophy, hypertension, and anthracycline-induced cardiotoxicity; (2) in vivo functional exploration using echocardiography, radiotelemetry, and Millar catheter probes for hemodynamic assessment; (3) ex vivo and in vitro assays including myograph and Langendorff isolated-heart preparations; and (4) consulting services for drug development and repositioning. Proprietary, validated disease models — notably a diet-induced NASH-HFpEF hamster model and the SDT fatty rat model for diabetic nephropathy — differentiate Cardiomedex's offering in the translational cardiovascular research market, where HFpEF and NASH-cardiac comorbidity have become high-priority indications for large-pharma pipelines.

Cardiomedex operates a project-based business model with custom-quoted, multi-year study contracts negotiated directly with client R&D teams, supplemented by consulting engagements. The company has no disclosed external funding and remains privately held. Customer acquisition is driven by direct sales, participation in major cardiology and metabolism conferences (AHA, ISHR, ISN, Keystone), peer-reviewed publications, and distribution partnerships such as the 2023 CLEA Japan agreement for the SDT fatty rat model. Cardiomedex also holds French Research Tax Credit (CIR) accreditation and operates in compliance with EU Directive 2010/63/EU for laboratory animal welfare, providing baseline eligibility for European preclinical outsourcing engagements.

cardiomedex firmographics

Firmographics
Name
cardiomedex
Legal name
Cardiomedex SAS
Website
https://cardiomedex.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Cardiomedex is a France-based preclinical CRO founded in 2011, providing contract research services for cardiovascular and cardiometabolic drug development. It serves global pharmaceutical and biotechnology clients with proprietary animal models, functional exploration platforms, ex vivo assays, and drug-repositioning consulting.
Ownership category
akta.pro rank

cardiomedex industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKABAA
General Cardiology (Consultative)

Keywords

  • Preclinical contract research
  • Cardiovascular drug development
  • Animal model studies
  • Cardiometabolic research
  • Preclinical CRO services

Where cardiomedex is headquartered

Location

Headquarters

HQ city
Escalquens
HQ country
France
HQ region
Europe

Offices2 records

Markets served

cardiomedex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Preclinical CRO Services: Contract research organization providing fee-for-service preclinical studies for pharmaceutical and biotechnology companies evaluating cardiovascular drug candidates. Services include in vivo models, ex vivo/in vitro assays, and pharmacological characterization.
  2. Consulting Services: Strategy consulting services including research strategy development, study design and protocol development, literature research, medical writing, and strategic portfolio reviews for drug development and repositioning.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom CRO service packages tailored to client specifications

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

cardiomedex product offering

Product offering

Core offering

Cardiomedex is a preclinical contract research organization (CRO) that provides fee-for-service preclinical studies for pharmaceutical and biotechnology companies developing cardiovascular and cardiometabolic drugs. Its offering combines three service lines: in vivo animal models (HFpEF, HFrEF, myocardial infarction, cardiac hypertrophy, hypertension, NASH, diabetic nephropathy), in vivo functional exploration (echocardiography, telemetry, hemodynamic measurements), and ex vivo/in vitro assays (vascular reactivity, Langendorff perfused heart), supplemented by drug development consulting.

Product overview

Cardiomedex is a preclinical Contract Research Organization (CRO) highly specialized in cardiovascular diseases and cardiometabolic complications. The company operates as a unified platform combining three interconnected service lines: In Vivo Models (pathophysiological animal models including HFpEF/HFrEF, myocardial infarction, cardiac hypertrophy, hypertension, and cardiometabolic models), In Vivo Exploration Platform (functional characterization via echocardiography, telemetry, hemodynamic measurements, and exercise testing), and Ex Vivo/In Vitro Assays (isolated organ studies and cellular assays). These core offerings are supplemented by personalized Consulting Services for drug development strategy, repositioning, and lifecycle management. Together, these services enable pharmaceutical and biotechnology companies to evaluate cardiac efficacy and safety of compounds using gold-standard and tailor-made experiments.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Successfully developed and validated NASH-HFpEF hamster model presented at AHA 2023 and ISHR 2023 conferences
  • +1 more outcomes

Companies that use cardiomedex

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

cardiomedex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

cardiomedex partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • CLEA Japan Inc.minorStrategic or Co-development Partner · 30 March 2023Collaborative partnership with CLEA Japan Inc. for the SDT fatty rat model development. CLEA Japan provides the SDT fatty rat model expertise and business development support. Presented collaborative work at ISN-World Congress of Nephrology in Bangkok, Thailand in March-April 2023.
  • PhysiogenexcoreStrategic or Co-development PartnerPhysiogenex is a preclinical CRO specialized in metabolic disorders based in Toulouse, France with 15+ years of expertise. Cardiomedex and Physiogenex share the same CEO (Dr. Thierry Sulpice) and facilities. Together they provide an integrated approach to cardiometabolic diseases, enabling large-scale studies evaluating drug candidates on both cardiac and metabolic functions. Cardiomedex is a subsidiary company of Physiogenex.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

cardiomedex competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Scientific: Large European-based CRO with extensive preclinical and clinical service lines, including cardiovascular safety pharmacology. Competes broadly for preclinical cardiovascular contracts across pharma sponsors.
  • Crown Bioscience: Global preclinical CRO with cardiovascular and metabolic disease models, including translational platforms for HFpEF, diabetes, and NASH. Competes with Cardiomedex on specialized cardiometabolic preclinical studies with greater geographic footprint.
  • WuXi AppTec: Asia-based global CRO/CDMO with preclinical capabilities including cardiovascular and metabolic disease models. Competes on scale, integrated offerings, and cost for outsourced preclinical studies.
  • Charles River Laboratories: Global preclinical CRO with cardiovascular safety and efficacy capabilities across multiple species and therapeutic areas. Broad incumbent that competes with Cardiomedex on large cardiovascular preclinical programs but at vastly greater scale.
  • Inotiv: US-based preclinical CRO with cardiovascular safety pharmacology, toxicology, and disease model capabilities. Competitor for North American sponsor preclinical cardiovascular programs.
  • Medpace: Mid-sized CRO with strong cardiovascular therapeutic area presence, primarily clinical but with preclinical-adjacent relationships. Comparable as a cardiovascular-focused CRO serving pharma/biotech sponsors, though predominantly clinical-phase.

Direct peers

  • Physiogenex: Sister preclinical CRO sharing the same CEO (Dr. Thierry Sulpice), facilities in Escalquens, and a cardiometabolic focus. Directly comparable as a similarly sized French preclinical CRO serving pharma/biotech with metabolic disease models.
  • Pelvipharm: French preclinical CRO specializing in vascular and women's health pharmacology, where Cardiomedex's Director of Business Development (Dr. Rana Assaly) was previously COO. Closely comparable in size, therapeutic niche, and French preclinical CRO model.

Emerging players

  • Reaction Biology: Preclinical CRO offering cardiovascular safety and efficacy profiling services. Comparable emerging player in specialized preclinical cardiovascular pharmacology for biotech sponsors.
  • Bienta (Enamine contract research): Preclinical CRO with in vivo pharmacology capabilities across metabolic and cardiovascular indications. Comparable as a smaller, emerging preclinical CRO competing for European biotech preclinical contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

cardiomedex social profiles

Digital presence

cardiomedex compliance and trust

Trust signal

Compliance2 records

cardiomedex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

cardiomedex leadership team

Management profile

Number of profiles

cardiomedex subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

cardiomedex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

cardiomedex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about cardiomedex

What does cardiomedex do?

Cardiomedex is a preclinical contract research organization (CRO) that provides fee-for-service preclinical studies for pharmaceutical and biotechnology companies developing cardiovascular and cardiometabolic drugs. Its offering combines three service lines: in vivo animal models (HFpEF, HFrEF, myocardial infarction, cardiac hypertrophy, hypertension, NASH, diabetic nephropathy), in vivo functional exploration (echocardiography, telemetry, hemodynamic measurements), and ex vivo/in vitro assays (vascular reactivity, Langendorff perfused heart), supplemented by drug development consulting.

Is cardiomedex a public or private company?

cardiomedex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was cardiomedex founded?

cardiomedex was founded in 2011. It employs 11 to 50 people.

Where is cardiomedex based?

cardiomedex is headquartered in Escalquens, France, in the Europe region.

How does cardiomedex make money?

Two revenue lines are on record. Preclinical CRO Services are the primary driver. The others are consulting Services.

Who are cardiomedex's main competitors?

Broad incumbents on record are Eurofins Scientific, Crown Bioscience, WuXi AppTec, Charles River Laboratories, Inotiv and Medpace. Direct peers are Physiogenex and Pelvipharm. Emerging players are Reaction Biology and Bienta (Enamine contract research).

Does cardiomedex have an API?

No public API is recorded for cardiomedex.

What industry is cardiomedex in?

cardiomedex's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 5417.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales